TIDMMDST

Medicsight Plc

05 July 2011

 
 Press Release   05 July 2011 
 

Medicsight PLC

("Medicsight" or "the Company")

Medicsight enters sponsorship agreement with MD Training @home

The future of physician training

Medicsight PLC (AIM: MDST), an industry leader in the development of Computer-Aided Detection (CAD) and medical image analysis software is pleased to announce it has entered into an agreement to provide exclusive CAD sponsorship for all CT colonography courses provided by MD Training @home (MDT).

MDT is a collection of interactive training programs focused on imaging modalities. MDT programs allow physicians to acquire training and CME accreditation using a convenient and cost-effective virtual model. The courses are designed to enhance the physician's clinical practice skills by providing online tools and remote-mentored training to interpret patient exams.

ColonCAD(TM) API is integrated within MDT's eLearning cloud solution, and will be utilised during hands-on CT colonography tutorials. ColonCAD(TM) API is an advanced Computer-Aided Detection algorithm which has been cleared for marketing in the United States by the Food and Drug Administration (FDA). ColonCAD(TM) has been clinically proven to significantly improve radiologists' overall performance when interpreting CT colonography images. The CAD analyses scan data and automatically highlight specific regions of interest that are indicative of potential colorectal polyps, thus helping radiologists to identify abnormalities within the colon that may be the early precursors of potential life threatening disease.

Allan Rowley, CEO of Medicsight, said: "Medicsight is committed to supporting and developing physician training. This partnership with MD Training @home demonstrates Medicsight's commitment to furthering clinical education and demonstrates the benefits ColonCAD(TM) API can provide for physicians during their interpretation of CT colonography examinations."

"This further extends our commitment to the physician training market by offering the most advanced technology to our customers," states Jeff Williams, COO of MD Training @home. "In today's heavily regulated and compliance driven environment, this partnership also provides Medicsight with excellent opportunities to maximise brand exposure to all physicians who participate."

ENDS -

For further information:

 
 Medicsight plc 
 Allan Rowley, CEO   Tel: +44 (0)207 605 7950 
                           www.medicsight.com 
                         follow us on twitter 
                                  @Medicsight 
 
 
 Daniel Stewart & Co 
 Noelle Greenaway / Oliver Rigby   Tel: +44 (0) 207 776 6550 
                                     www.danielstewart.co.uk 
 

Media enquiries:

 
 Abchurch 
                                       www.abchurch-group.com 
 Julian Bosdet                      Tel: +44 (0) 207 398 7700 
 julian.bosdet@abchurch-group.com 
 Adam Michael                       Tel: +44 (0) 207 398 7708 
 adam.michael@abchurch-group.com 
 Simone Elviss                      Tel: +44 (0) 207 398 7728 
 simone.elviss@abchurch-group.com 
 Quincy Allan                       Tel: +44 (0) 207 398 7710 
 quincy.allan@abchurch-group.com 
 

Notes to editors

Medicsight plc is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD software has been developed using a large and population diverse database of verified patient CT scan data. Medicsight's ColonCAD(TM) software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

About Computer-Aided Detection

With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations generate as many as 2000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This can be critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful treatment and a positive therapeutic outcome. In addition to supporting individual radiologists CAD also has the potential to help standardise CT interpretation across both individuals and institutions thereby supporting population based screening programmes.

About Medicsight's CAD software

Medicsight's ColonCAD(TM) software uses an advanced CAD algorithm to analyse CT scans of the colon and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon.

ColonCAD can be seamlessly integrated with advanced 3D visualisation platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease.

Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be validated to the highest possible standards.

About colorectal cancer

According to the American Cancer Society, colorectal cancer is one of the leading causes of cancer-related deaths in the United States with an estimated 49,000 colorectal cancer deaths expected during 2011. However regular screening (where polyps can be detected at an early stage before they have developed into cancer) is one of the most powerful methods of colorectal cancer prevention. Screening for colorectal polyps increases the probability of more colorectal cancers being detected earlier - when the disease is easier to cure.

About MD Training@Home

MD Training@home a leading provider of interactive home and web-based medical training programs enables physicians to gain continuing medical education (CME) accreditation and annual case review requirements from the convenience of their home or office. Specialties available include CT colonography and cardiac courses.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAUGUUPMUPGGMC

Medicsight (LSE:MDST)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Medicsight Charts.
Medicsight (LSE:MDST)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Medicsight Charts.